By 2030, the market is forecasted to reach USD 289.06 million , contributing USD 46.36 million during the first half of the decade
It may differ by pharmacies
Since then, the mechanisms and benefits of GLP-1s have become better understood and revealed new opportunities where they could potentially be used in the treatment of additional conditions
Several firms that initially covered GLP-1 drugs for weight loss have since restricted coverage to only cover GLP-1 agonists for employees with specific medical indications, like diabetes
This approach helps minimize side effects while allowing the body to adapt to the treatment
Semaglutide helps slow down digestion, which means overeating or eating foods that take a long time to digest could result in nausea, stomach pain, gas, bloating, constipation, or diarrhea